Abstract
A Phase 2a Study Evaluating the Safety and Pharmacokinetics (PK) of Luspatercept in Pediatric Patients with Transfusion-Dependent β-Thalassemia (TDT)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have